Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
95,639
-
Share change
-
+95,639
-
Total reported value
-
$405,000
-
Price per share
-
$4.23
-
Number of holders
-
4
-
Value change
-
+$405,000
-
Number of buys
-
4
Institutional Holders of MABVAX THERAPEUTICS HLDGS IN - COM NEW (MBVX) as of Q3 2016
As of 30 Sep 2016,
MABVAX THERAPEUTICS HLDGS IN - COM NEW (MBVX) was held by
4 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
95,639 shares.
The largest 4 holders included
KCG Holdings, Inc., Biomark Capital Management Co. LLC, Tower Research Capital LLC (TRC), and UBS Group AG.
This page lists
4
institutional shareholders reporting positions in this security
for the Q3 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.